Loriot Y - Search Results

1

Association between lymphoma and melanoma: report of a single-center series of eight patients and a review of the literature.

Loriot Y, Chaoui D, Dorval T, Vincent-Salomon A, Lumbroso-Le Rouic L, Dendale R, Desjardins L, Levy C, Decaudin D. Loriot Y, et al. Leuk Lymphoma. 2006 Jun;47(6):1023-8. doi: 10.1080/10428190500464187. Leuk Lymphoma. 2006. PMID: 16840192

2

Targeted therapy-induced radiation recall.

Levy A, Hollebecque A, Bourgier C, Loriot Y, Guigay J, Robert C, Delaloge S, Bahleda R, Massard C, Soria JC, Deutsch E. Levy A, et al. Among authors: loriot y. Eur J Cancer. 2013 May;49(7):1662-8. doi: 10.1016/j.ejca.2012.12.009. Epub 2013 Jan 8. Eur J Cancer. 2013. PMID: 23312391

3

Compliance with guidelines and correlation with outcome in patients with advanced germ-cell tumours.

Thibault C, Fizazi K, Barrios D, Massard C, Albiges L, Baumert H, Patard JJ, Escudier B, Loriot Y. Thibault C, et al. Among authors: loriot y. Eur J Cancer. 2014 May;50(7):1284-90. doi: 10.1016/j.ejca.2014.01.026. Epub 2014 Feb 20. Eur J Cancer. 2014. PMID: 24560488

4

Pemetrexed-induced pneumonitis: a case report.

Loriot Y, Ferte C, Gomez-Roca C, Moldovan C, Bahleda R, Wislez M, Cadranel J, Soria JC. Loriot Y, et al. Clin Lung Cancer. 2009 Sep;10(5):364-6. doi: 10.3816/CLC.2009.n.050. Clin Lung Cancer. 2009. PMID: 19808196

5

Differential expression of biomarkers in men and women.

Planchard D, Loriot Y, Goubar A, Commo F, Soria JC. Planchard D, et al. Among authors: loriot y. Semin Oncol. 2009 Dec;36(6):553-65. doi: 10.1053/j.seminoncol.2009.09.004. Semin Oncol. 2009. PMID: 19995647 Review.

6

Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study.

Oing C, Oechsle K, Necchi A, Loriot Y, De Giorgi U, Fléchon A, Daugaard G, Fedyanin M, Faré E, Bokemeyer C. Oing C, et al. Among authors: loriot y. Ann Oncol. 2017 Mar 1;28(3):576-582. doi: 10.1093/annonc/mdw648. Ann Oncol. 2017. PMID: 27993806 Free article.

7

The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer.

Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, Chauchereau A, Fizazi K. Loriot Y, et al. Eur J Cancer. 2010 Jul;46(10):1770-2. doi: 10.1016/j.ejca.2010.04.010. Epub 2010 May 17. Eur J Cancer. 2010. PMID: 20483588

8

Carcinomas of an unknown primary origin--diagnosis and treatment.

Massard C, Loriot Y, Fizazi K. Massard C, et al. Among authors: loriot y. Nat Rev Clin Oncol. 2011 Nov 1;8(12):701-10. doi: 10.1038/nrclinonc.2011.158. Nat Rev Clin Oncol. 2011. PMID: 22048624 Review.

9

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.

Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, Gleave M, Fizazi K, Loriot Y. Al Nakouzi N, et al. Among authors: loriot y. Eur Urol. 2015 Aug;68(2):228-35. doi: 10.1016/j.eururo.2014.04.015. Epub 2014 May 2. Eur Urol. 2015. PMID: 24837187

10

Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301.

Montgomery B, Kheoh T, Molina A, Li J, Bellmunt J, Tran N, Loriot Y, Efstathiou E, Ryan CJ, Scher HI, de Bono JS. Montgomery B, et al. Among authors: loriot y. Eur Urol. 2015 May;67(5):866-73. doi: 10.1016/j.eururo.2014.06.042. Epub 2014 Jul 10. Eur Urol. 2015. PMID: 25018037 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

310 results

Search Page

Filters